TIRZ
Tirzepatide
A synthetic 39-amino-acid peptide built on the sequence of glucose-dependent insulinotropic polypeptide and carrying a C20 fatty diacid on a lysine side chain. It is an agonist at two receptors rather than one: the GIP receptor and the GLP-1 receptor. That dual activity is the structural difference between it and the single-receptor GLP-1 analogues listed elsewhere in this market.
Tirzepatide has 222 registered human studies on ClinicalTrials.gov, reaching phase 4, covering 85,102 planned or enrolled participants across the 197 studies that published a figure. An FDA-approved product contains Tirzepatide — ZEPBOUND (NDA217806). 2,314 papers naming it were published in the last ten years.
Collected 2026-08-02 from ClinicalTrials.gov and Drugs@FDA. Counts include only trials whose registered intervention names Tirzepatide; the registry search is fuzzy, so every match is re-checked. None of this says whether Tirzepatide works or is safe.
FDA status
Approved
Human studies
222
Furthest phase
Phase 4
Papers, 10 yr
2,314
Readership
38,322
monthly average, Feb–Jun 2026
Tracking since 2026-07-29 · About this data
What has actually been tested in humans
An approved product exists
222
Registered human studies
Phase 4
Furthest phase reached
85,102
Planned or enrolled participants, across 197 studies that published a figure
Approved
FDA-approved product — ZEPBOUND
270 loose registry matches were checked and 222 confirmed — 48 named something else and were discarded. We count a study only when Tirzepatide is named as an intervention in it.
Registered means registered — not that the study finished, and not that it found anything. The grade is mechanical: it is computed from the registry and the FDA record alone, and it grades how much is known, never whether a compound is good or safe. Collected 2026-08-02 from ClinicalTrials.gov and Drugs@FDA. Check the query.
What Tirzepatide is, and what it has been studied for
Tirzepatide is classified by ChEMBL as a protein, and appears in trial registrations under BG-121 and LY-3298176. Its FDA substance identifier is OYN3CCI6QE.
Across 222 registered trials, it has been studied in Obesity, Overweight, Type 2 Diabetes and Obesity & Overweight. A condition here is what a sponsor registered the trial under — it records what was investigated, not what was shown.
The trials were run by Eli Lilly and Company and Brigham and Women's Hospital among others. A named commercial sponsor means a compound is in formal development; its absence does not mean the opposite, only that no company has registered a trial under its own name.
How far it got
Tirzepatide reached Phase 4 across 222 registered trials.
An FDA-approved product contains Tirzepatide. Approval covers a specific product for a specific use — it is not a verdict on the molecule.
Is anyone studying Tirzepatide?
Papers published each year that name Tirzepatide in the title or abstract, with the clinical trials that started in the same year marked beneath. Ten calendar years.
| Year | Publications | Trials started | Complete year |
|---|---|---|---|
| 2017 | 0 | 4 | Yes |
| 2018 | 0 | 2 | Yes |
| 2019 | 0 | 13 | Yes |
| 2020 | 10 | 9 | Yes |
| 2021 | 36 | 6 | Yes |
| 2022 | 112 | 8 | Yes |
| 2023 | 221 | 20 | Yes |
| 2024 | 396 | 36 | Yes |
| 2025 | 905 | 55 | Yes |
| 2026 | 861 | 68 | No |
2,314 papers and 221 registered trials between 2017 and 2026. A paper counts when “Tirzepatide” appears in its title or abstract — phrase-matched, so a paper mentioning the words separately is not counted. The total is a single query over the whole window, which is why it does not equal the bars added together: PubMed files a paper under both its electronic and its print publication date, so one paper can appear in two years. Publication volume measures scientific attention, not whether a compound works: a well-studied compound can be well-studied and ineffective. Sources: PubMed and ClinicalTrials.gov · collected 2026-08-02.
What Tirzepatide costs through a legal channel
Published cash prices, per month, as each programme states them. Sorted cheapest first. These are prices for an approved product dispensed through a pharmacy — not the research channel, which publishes no price this site collects.
- $299/mocash price
Collected 2026-07-31 from each programme’s own published pages. Cheapest is not a recommendation — these channels differ in who prescribes, who dispenses and who is accountable, and a price says nothing about which is appropriate for anyone. Prices change without notice; the seller’s page is authoritative. Check the source.
Published research on Tirzepatide
2,314 indexed papers name Tirzepatide in their title or abstract. These are the 8 PubMed ranks most relevant. Listing a paper is not a judgement about it, and none of these is summarised here — follow the link and read what it says.
- Tirzepatide as Compared with Semaglutide for the Treatment of Obesity
- Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
- Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis
- Semaglutide vs Tirzepatide for Weight Loss in Adults With Overweight or Obesity
- Tirzepatide: A Systematic Update
- Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial
- Tirzepatide for overweight and obesity management
- Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial
Collected 2026-08-02from PubMed, phrase-matched on “Tirzepatide” in title and abstract. Run the same search.
About Tirzepatide
A synthetic 39-amino-acid peptide built on the sequence of glucose-dependent insulinotropic polypeptide and carrying a C20 fatty diacid on a lysine side chain. It is an agonist at two receptors rather than one: the GIP receptor and the GLP-1 receptor. That dual activity is the structural difference between it and the single-receptor GLP-1 analogues listed elsewhere in this market.
- Also known as
- LY3298176
- Source
- ebi.ac.uk ↗
Structure and mechanism only. Nothing above describes what this compound is for, and no dose appears anywhere on this page.
Reading on this compound
All articles →PepRack articles that reference this compound. This is not a news feed — we syndicate nothing and publish no datelines.
Vendor listings are not affiliate links and PepRack earns nothing from them. A listing records a price we observed on a date. It is not a recommendation of a product, dose, or treatment, and PepRack does not verify what any vendor ships.